Clinical pharmacology and therapeutics
-
Clin. Pharmacol. Ther. · Feb 2015
EditorialPharmacological treatment of pain: future trends and novel insights.
The pharmacological treatment of chronic pain is generally hampered by a limited clinical outcome. Hence, there is a strong need for new therapeutic concepts considering the identification of novel targets and related drugs, but also optimization of established therapeutic regimes through individualization. In this issue, focused on "Pain," we discuss some of the recent new concepts in pain treatment, understanding of pain heterogeneity, and subsequent optimization of analgesic treatment, but also novel insights into interactions of nonopioids.
-
Clin. Pharmacol. Ther. · Feb 2014
EditorialManaging the innovation supply chain to maximize personalized medicine.
Personalized medicine epitomizes an evolving model of care tailored to the individual patient. This emerging paradigm harnesses radical technological advances to define each patient's molecular characteristics and decipher his or her unique pathophysiological processes. Translated into individualized algorithms, personalized medicine aims to predict, prevent, and cure disease without producing therapeutic adverse events. ⋯ We often consider the flow of innovation and technology along a continuum of discovery, development, regulation, and application bridging the bench with the bedside. However, this process also can be viewed through a complementary prism, as a necessary supply chain of services and providers, each making essential contributions to the development of the final product to maximize value to consumers. Considering personalized medicine in this context of supply chain management highlights essential points of vulnerability and/or scalability that can ultimately constrain translation of the biological revolution or potentiate it into individualized diagnostics and therapeutics for optimized value creation and delivery.
-
The landscape for bioinnovation is undergoing a seismic shift as drug developers, regulators, academic institutions, and government research organizations adapt to the formidable challenge of bringing new medicines to market. The inability to translate current advances in the scientific understanding of disease into new therapeutics is forcing all sectors to replace traditional drug development paradigms with newer and more efficient models. This issue of Clinical Pharmacology & Therapeutics explores these changes to the bioinnovation ecosystem.
-
Clin. Pharmacol. Ther. · Jun 2012
EditorialTranslational bioinformatics: data-driven drug discovery and development.
Internet-accessible computing power and data-sharing mandates now enable researchers to interrogate thousands of publicly available databases containing molecular, clinical, and epidemiological data. With emerging new approaches, translational bioinformatics can now provide answers to previously untouchable questions, ranging from detecting population signals of adverse drug reactions to clinical interpretation of the whole genome. There are challenges, including lack of access to some data sources and software, but there are also overwhelming doses of hopes and expectations.